This trial is active, not recruiting.

Conditions colorectal cancer, lynch syndrome, hnpcc
Treatment observation
Sponsor Vejle Hospital
Start date October 2012
End date February 2015
Trial size 5000 participants
Trial identifier NCT01845753, MS-LS-DK-02


A clinically applicably strategy for molecular screening for Lynch Syndrome is being implemented in Denmark.

Based on sequential analysis with immunohistochemistry and methylation analysis, patients with possible hereditary colorectal cancer are identified. These patients are offered genetic risk assessment and counselling.

The study hypothesis is that molecular screening will identify more patients with Lynch Syndrome than the family history alone.

Prospective data collection is performed using established clinical databases.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Rate of Lynch Syndrome in a population of primary colorectal cancer
time frame: 1 year

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Histological diagnosis of colorectal adenocarcinoma - Diagnosed at one of the departments of pathology in Denmark Exclusion Criteria:

Additional Information

Official title Molecular Screening for Lynch Syndrome in Denmark
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by Vejle Hospital.